DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$12.24
-0.57 (-4.45%)
Open$12.81
Previous Close$12.81
Day High$12.88
Day Low$12.24
52W High$17.25
52W Low$5.28
Volume—
Avg Volume772.1K
Market Cap794.16M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+381.6% upside
Current
$12.24
$12.24
Target
$58.95
$58.95
$40.84
$58.95 avg
$77.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 133.74M | 128.39M | 127.15M |
| Net Income | -5,858,142 | -5,637,576 | -5,243,986 |
| Profit Margin | -4.4% | -4.4% | -4.1% |
| EBITDA | -5,607,781 | -6,075,682 | -5,861,844 |
| Free Cash Flow | -4,251,021 | -4,814,286 | -3,496,781 |
| Rev Growth | +7.4% | +3.0% | +5.7% |
| Debt/Equity | 0.91 | 1.04 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |